APP and Alzheimer disease: Moreover, necroptosis was postulated to exacerbate cognitive deficits in the APP/PS1 mouse model of AD, since treatment with the RIPK1 inhibitor necrostatin-1 reduced neuronal death, attenuated the formation of insoluble Aβ plaques and hyperphosphorylated tau in the cortex and hippocampus and ameliorated cognitive impairment [62, 63].